RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $38.5 which represents a slight increase of $2.61 or 7.27% from the prior close of $35.89. The stock opened at $36.35 and touched a low ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Moderna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines ...

The measure would seem a premptive strike at a growing industry. No food engineered to include vaccines are approved for use ...

Following the lead of previous work on mRNA-based vaccines, therapies for spinal cord injuries and more, the method relies upon mineral-coated microparticles to deliver mRNA that encodes for ...